{"filings":[{"id":254238,"accession_number":"0001437749-24-003695","cik":86115,"company_name":"SAFEGUARD SCIENTIFICS INC","ticker":"SFES","form_type":"8-K","filed_at":"2024-02-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Safeguard Scientifics voluntarily transfers listing from Nasdaq to OTCQX Best Market under symbol SFES","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Begins trading on OTCQX effective February 12, 2024 under symbol SFES.","Voluntary transfer from Nasdaq; OTCQX requires high financial standards and corporate governance.","Press release issued by OTC Markets Group; no financial updates or changes in operations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":8194266.769230769,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254237,"accession_number":"0001104659-24-009791","cik":86115,"company_name":"SAFEGUARD SCIENTIFICS INC","ticker":"SFES","form_type":"8-K","filed_at":"2024-02-02T23:59:59+00:00","items":["3.01","7.01","9.01"],"status":"ready","headline":"Safeguard Scientifics files Form 25 to voluntarily delist from Nasdaq, expects suspension Feb 12","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Filed Form 25 with SEC on Feb 2, 2024 to voluntarily delist common stock from Nasdaq.","Trading suspended effective Feb 12, 2024 prior to market open; plans to file Form 15 thereafter.","Intends to deregister under Section 12(g) by certifying fewer than 300 shareholders of record.","Shares may trade on OTC Markets Group, but no guarantee of broker market making or continued trading."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8194266.769230769,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254236,"accession_number":"0001437749-24-001865","cik":86115,"company_name":"SAFEGUARD SCIENTIFICS INC","ticker":"SFES","form_type":"8-K","filed_at":"2024-01-22T23:59:59+00:00","items":["3.01","8.01","7.01","9.01"],"status":"ready","headline":"Safeguard Scientifics to voluntarily delist from Nasdaq on Feb 2, 2024; plans to deregister","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed notice to delist common stock from Nasdaq via Form 25 on February 2, 2024.","Delisting expected 10 days post-filing; will then file Form 15 to deregister under Exchange Act.","After delisting, trading may occur on OTC Markets, but no guarantee of a market maker.","Executed a 1-for-100 reverse stock split followed by 100-for-1 forward split, effective January 12, 2024.","Board approved the delisting and deregistration plan on December 15, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":8194266.769230769,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254235,"accession_number":"0001104659-24-001868","cik":86115,"company_name":"SAFEGUARD SCIENTIFICS INC","ticker":"SFES","form_type":"8-K","filed_at":"2024-01-05T23:59:59+00:00","items":["8.01","5.02","7.01","9.01"],"status":"ready","headline":"Safeguard Scientifics sets Jan 12 for stock splits to enable going dark; names Mark Dow CEO/CFO","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["1-for-100 reverse split then 100-for-1 forward split effective Jan 12; trading on Nasdaq post-split Jan 16.","Shareholders with <100 shares receive $1.65/share cash for fractional shares; ≥100 shares unchanged.","Company to file Form 25 to delist from Nasdaq; then Form 15 to deregister under Exchange Act.","Mark Dow (Rock Creek) appointed CEO, CFO, Secretary effective Jan 1; prior officers Salzman and Herndon departed Dec 31.","Company plans to seek quotation on OTC Markets; no guarantee of active market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":8194266.769230769,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271721,"accession_number":"0001104659-23-126909","cik":86115,"company_name":"SAFEGUARD SCIENTIFICS INC","ticker":"SFES","form_type":"8-K","filed_at":"2023-12-18T23:59:59+00:00","items":["8.01","1.01","3.01","5.02","5.07","7.01","9.01"],"status":"ready","headline":"Safeguard Scientifics to delist from Nasdaq after 1-for-100 reverse split; special dividend $0.35","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved reverse stock split 1-for-100 followed by forward split 100-for-1 to reduce record holders below 300.","Holders with <100 shares pre-split receive $1.65 per share cash; continuing shareholders' total shares unchanged.","Special cash dividend of $0.35 per share payable Dec 28, 2023; ex-div Dec 29; record Dec 19.","CEO Salzman and CFO Herndon terminated as officers Dec 31, 2023; become temporary employees at $400/hr; Rock Creek outsourced services at $25k/month.","Company will file Form 25 to delist from Nasdaq and Form 15 to terminate SEC reporting obligations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":8194266.769230769,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271720,"accession_number":"0001104659-23-124747","cik":86115,"company_name":"SAFEGUARD SCIENTIFICS INC","ticker":"SFES","form_type":"8-K","filed_at":"2023-12-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Safeguard Scientifics declares $0.35 special dividend contingent on reverse/forward stock split and going private","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["Special cash dividend of $0.35 per share, payable Dec 28 to holders of record Dec 19.","Dividend contingent on shareholder approval of reverse and forward stock split at Dec 15 special meeting.","Payment part of plan to cease SEC registration and delist from Nasdaq (going-private transaction).","Shares will trade with due bills from record date through payment date (Dec 19-28); ex-div Dec 29.","Company expects dividend treated as return of capital for U.S. federal tax purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8194266.769230769,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271719,"accession_number":"0001437749-23-030023","cik":86115,"company_name":"SAFEGUARD SCIENTIFICS INC","ticker":"SFES","form_type":"8-K","filed_at":"2023-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Safeguard Scientifics Q3 net income $0.9M, vs loss $3.2M; cash $15.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net income $0.9M ($0.06 diluted EPS) vs net loss $3.2M ($0.19 loss) in Q3 2022.","9M net loss narrowed to $5.4M ($0.33 loss) from $9.4M ($0.57 loss) year earlier.","Cash and equivalents $15.7M; carrying value of ownership interests $14.8M (cost $122.8M).","InfoBionic recap reduced ownership to ~5% with $1.7M non-cash gain; Trice Medical recap resulted in de minimis stake.","Aggregate trailing 12-month revenue of six portfolio companies $96M, up 10.3% YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8194266.769230769,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271718,"accession_number":"0001104659-23-107243","cik":86115,"company_name":"SAFEGUARD SCIENTIFICS INC","ticker":"SFES","form_type":"8-K","filed_at":"2023-10-05T23:59:59+00:00","items":["8.01","5.02","7.01","9.01"],"status":"ready","headline":"Safeguard Scientifics board approves plan to go private via stock splits, delist from Nasdaq","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split (1:50 to 1:100) followed by forward split; small holders cashed out at $1.65/share.","Estimated 4,305 shares (0.026% outstanding) cashed out; aggregate cost ~$1.2M (cash-on-hand).","Annual cost savings projected at ~$1.5M cash and ~$1.2M stock-based compensation reduction.","CEO Eric Salzman to depart Dec 31, 2023; board to reduce to two members; external service provider planned.","Company anticipates declaring dividend in Q4 2023, subject to board approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8194266.769230769,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":288568,"accession_number":"0001437749-23-023041","cik":86115,"company_name":"SAFEGUARD SCIENTIFICS INC","ticker":"SFES","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Safeguard Scientifics Q2 2023 net loss of $2.9M; six portfolio co. revenue up 12.8%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q2 2023 of $2.9M ($0.18/sh) vs net income $0.5M ($0.03/sh) in Q2 2022.","Cash, cash equivalents & restricted cash total $15.1M at June 30, 2023.","Deployed $3.0M to Prognos; received $0.4M from Aktana note sale; no material position in Aktana after recap.","Aggregate trailing 12-month revenue for six portfolio companies $95M, up 12.8% YoY.","Corporate expenses fell 12.2% to $0.7M in Q2 2023 from $0.8M in Q2 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8194266.769230769,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309115,"accession_number":"0001437749-23-015876","cik":86115,"company_name":"SAFEGUARD SCIENTIFICS INC","ticker":"SFES","form_type":"8-K","filed_at":"2023-05-25T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Safeguard Scientifics shareholders approve all four proposals at 2023 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected directors DeMont, Glass, Manko, Michelson with >7.3M votes each.","Advisory say-on-pay approved: 8.4M for, 1.8M against, 100K abstain.","Shareholders voted for annual say-on-pay frequency: 9.8M for one year.","Ratified Grant Thornton as auditor: 13.3M for, 29K against, 120K abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":8194266.769230769,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309114,"accession_number":"0001437749-23-012573","cik":86115,"company_name":"SAFEGUARD SCIENTIFICS INC","ticker":"SFES","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Safeguard Scientifics Q1 net loss narrows to $3.5M; in advanced deal talks","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $3.5M ($0.22/sh) vs $6.7M loss in Q1 2022; cash $18.8M.","Sold Bright Health interest for $850k; deployed $3.0M to Prognos post-Q1.","Reduced FY2023 deployment expectation to $3.0-4.5M from $4.0-6.0M.","Advanced discussions with single counterparty for strategic transaction; no deal yet.","G&A $1.2M and corporate expenses $0.8M, down 4-6% YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":8194266.769230769,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":327877,"accession_number":"0001437749-23-006317","cik":86115,"company_name":"SAFEGUARD SCIENTIFICS INC","ticker":"SFES","form_type":"8-K","filed_at":"2023-03-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Safeguard reports no direct SVB exposure; seven portfolio cos have deposits, $9M undrawn loans","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Safeguard has no banking relationship with Silicon Valley Bank.","Seven ownership interests have deposits, loans, or undrawn credit lines with SVB.","One other portfolio company (approx 2% stake) has significant SVB deposits.","FDIC's full depositor protection is expected to allow normal operations for those seven.","Two companies had $9M aggregate undrawn SVB loan commitments; alternative financing being sought."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":8194266.769230769,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":327876,"accession_number":"0001437749-23-005972","cik":86115,"company_name":"SAFEGUARD SCIENTIFICS INC","ticker":"SFES","form_type":"8-K","filed_at":"2023-03-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Safeguard Scientifics posts FY2022 net loss of $14.3M vs net income of $27.0M in 2021","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2022 $4.9M ($0.30/share) vs loss $8.6M ($0.51) in Q4 2021; FY2022 net loss $14.3M ($0.87) vs net income $27.0M ($1.36) in FY2021.","Cash & securities $19.3M at Dec 31, 2022; carrying value of ownership interests $15.4M.","Annual deployments $5.7M within prior guidance of $5M-$9M; funded loans to meQuilibrium and Trice Medical.","Repurchased 711,481 shares for $2.9M in 2022 at avg $4.13; added 736,577 shares through Jan 2023 under $3M plan.","Operating costs down 33% YoY: G&A $4.8M in 2022 vs $7.2M in 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8194266.769230769,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":327875,"accession_number":"0001437749-23-000766","cik":86115,"company_name":"SAFEGUARD SCIENTIFICS INC","ticker":"SFES","form_type":"8-K","filed_at":"2023-01-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Safeguard completes $3M share repurchase program; reports $19.3M cash at year-end","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Repurchased 736,577 shares at avg $4.09/share under $3M plan announced March 2022.","In 2022, repurchased 711,481 shares for $2.9M at avg $4.13; balance bought in Jan 2023.","Cash, equivalents, restricted cash, and marketable securities: $19.3M as of Dec 31, 2022.","Full-year 2022 deployments totaled $5.7M, within prior guidance of $5M-$9M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":8194266.769230769,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":327874,"accession_number":"0001437749-23-000347","cik":86115,"company_name":"SAFEGUARD SCIENTIFICS INC","ticker":"SFES","form_type":"8-K","filed_at":"2023-01-04T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CEO Eric Salzman enters new employment agreement through Dec 31, 2023; base salary $500K","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Base salary of $500,000 per year; term runs Jan 1, 2023 to Dec 31, 2023.","Restricted stock grant of 125,000 shares (monthly vesting over term) and performance RSU for 125,000 shares.","Severance: unpaid base salary for remainder of term, COBRA, and equity acceleration upon termination without cause or resignation for good reason.","All unvested equity accelerates upon a Change of Control during the term.","Amends and restates prior employment agreement dated Dec 21, 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":8194266.769230769,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":345549,"accession_number":"0001437749-22-025767","cik":86115,"company_name":"SAFEGUARD SCIENTIFICS INC","ticker":"SFES","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Safeguard Scientifics Q3 2022 net loss $3.2M vs prior-year net income $18.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Received $5.3M initial cash proceeds from Lumesis acquisition, recording a gain of $4.7M.","Funded $1.6M convertible note in Syapse's $35M growth capital round; capital to expand real-world insights for cancer.","Trailing 12-month revenues for eight portfolio companies were $139M, up 10.7% YoY.","Repurchased 84,261 shares in Q3 at avg $4.00; YTD repurchases 453,535 shares for $2.1M.","Operating costs reduced: G&A expenses $1.4M vs $1.6M in prior-year quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":8194266.769230769,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":345548,"accession_number":"0001437749-22-024171","cik":86115,"company_name":"SAFEGUARD SCIENTIFICS INC","ticker":"SFES","form_type":"8-K","filed_at":"2022-10-14T23:59:59+00:00","items":["3.01","7.01","9.01"],"status":"ready","headline":"Safeguard Scientifics transfers listing from NYSE to Nasdaq Capital Market, effective Oct 26","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Voluntary withdrawal from NYSE; trading ends Oct 25, begins on Nasdaq Oct 26, 2022.","Common stock will trade under the same ticker symbol SFE on Nasdaq Capital Market.","CEO cites cost savings and greater corporate flexibility for shareholders as rationale.","Listing on Nasdaq has been approved; no change in ticker or par value of shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":8194266.769230769,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":361996,"accession_number":"0001437749-22-023246","cik":86115,"company_name":"SAFEGUARD SCIENTIFICS INC","ticker":"SFES","form_type":"8-K","filed_at":"2022-09-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Safeguard Scientifics exits Lumesis via sale to SOLVE Advisors for $5.3M initial cash","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Safeguard received $5.3M initial cash proceeds from sale of Lumesis stake to SOLVE Advisors.","Additional cash may come from final net working capital adjustments and escrow contingencies.","Safeguard deployed $5.6M to Lumesis since 2012; expects to report a gain in Q3 2022.","CEO Eric Salzman highlighted progress on portfolio monetization for shareholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8194266.769230769,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":361995,"accession_number":"0001437749-22-020135","cik":86115,"company_name":"SAFEGUARD SCIENTIFICS INC","ticker":"SFES","form_type":"8-K","filed_at":"2022-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Safeguard Scientifics reports Q2 net income of $0.5M; Moxe dilution gain; exploring strategic alternatives","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income of $0.5M ($0.03/diluted EPS) vs net loss of $0.3M ($0.02 loss/share) in Q2 2021.","Moxe raised $30M equity, diluting Safeguard's ownership to 19.4%, generating a $5.3M non-cash dilution gain.","Repurchased 221,479 shares in Q2 at avg $4.27, totaling $0.9M; remaining authorization $1.1M.","Continues working with Houlihan Lokey to explore strategic alternatives to maximize shareholder value.","Expects 2022 corporate expenses at low-end or below $3.5-4.0M; deployments may hit upper half of $5-9M range."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8194266.769230769,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":381474,"accession_number":"0001437749-22-013761","cik":86115,"company_name":"SAFEGUARD SCIENTIFICS INC","ticker":"SFES","form_type":"8-K","filed_at":"2022-05-27T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Shareholders elect two new directors, approve executive compensation and auditor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ross D. DeMont and Beth S. Michelson elected to board; DeMont to chair Compensation Committee.","DeMont is CIO at Rainin Group; Michelson is SMD at Cartesian Capital and CFO of two SPACs.","Advisory vote on executive compensation passed with ~7.9M for, ~1.8M against, ~152k abstain.","Grant Thornton LLP ratified as independent auditor for FY2022 with ~12.6M votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":8194266.769230769,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":381473,"accession_number":"0001437749-22-011133","cik":86115,"company_name":"SAFEGUARD SCIENTIFICS INC","ticker":"SFES","form_type":"8-K","filed_at":"2022-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Safeguard Scientifics Q1 net loss $6.7M; strategic review with Houlihan Lokey continues","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $6.7M ($0.40 per share) vs net income $17.6M ($0.84 per share) in Q1 2021.","Repurchased 147,795 shares at avg $5.27 in Q1; additional $0.4M post-quarter at $4.71.","Funded $2.0M convertible loan to Prognos Health and $1.4M to Clutch Holdings.","Carrying value of ownership interests $24.1M vs cost $154.4M; Bright Health fair value $2.6M.","Strategic review with Houlihan Lokey ongoing; update expected by Q3 2022 earnings call."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8194266.769230769,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":399459,"accession_number":"0001437749-22-006779","cik":86115,"company_name":"SAFEGUARD SCIENTIFICS INC","ticker":"SFES","form_type":"8-K","filed_at":"2022-03-21T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Safeguard Scientifics authorizes $3M share repurchase, replacing prior $6M plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New $3M buyback replaces $6M plan announced May 2021; expects completion by end of 2022.","Prior plan repurchased 236,159 shares at avg $6.94/share for $1.6M before suspension.","CEO says current share price does not reflect portfolio fair value; repurchase is prudent.","Company funded ~$1.4M to Clutch Holdings; YTD deployments $3.4M vs FY estimate $5-9M.","No material developments in strategic alternatives evaluation with Houlihan Lokey; outcome uncertain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":8194266.769230769,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":399458,"accession_number":"0001437749-22-005699","cik":86115,"company_name":"SAFEGUARD SCIENTIFICS INC","ticker":"SFES","form_type":"8-K","filed_at":"2022-03-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Safeguard Scientifics reports $60.8M cash proceeds from 2021 exits; initiates strategic review","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Repurchased 4.5M shares in 2021, including 4.3M via Dutch auction at $9.06 per share.","Received $44.8M from Flashtalking exit, $32.5M gain; $3.5M cash + $15.3M preferred equity from Zipnosis.","BHG IPO converted preferred to 1.3M common shares; fair value fell to $4.5M by year-end.","Deployments totaled $2.7M in 2021; funded $2M convertible loan to Prognos Health post-year-end.","Board initiated evaluation of strategic alternatives to enhance shareholder value."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":8194266.769230769,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":418439,"accession_number":"0001437749-21-029044","cik":86115,"company_name":"SAFEGUARD SCIENTIFICS INC","ticker":"SFES","form_type":"8-K","filed_at":"2021-12-21T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CEO Eric Salzman enters amended employment agreement through Dec 2022 with $500K salary and equity grants","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual base salary of $500,000; term ends December 31, 2022.","Receives restricted stock award of 60,000 shares vesting monthly over 12-month term.","Receives performance-based RSU for 80,000 shares, vesting on criteria met during term.","All unvested equity accelerates on termination without Cause, for Good Reason, or Change of Control.","Severance includes unpaid base salary lump sum, COBRA coverage, and full equity vesting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":8194266.769230769,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":418438,"accession_number":"0001437749-21-025299","cik":86115,"company_name":"SAFEGUARD SCIENTIFICS INC","ticker":"SFES","form_type":"8-K","filed_at":"2021-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Safeguard posts Q3 net income of $18.3M ($0.88 per share); completes $38.7M self-tender","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Repurchased 4.3M shares for $38.7M via modified Dutch auction self-tender completed Oct 7, 2021.","Flashtalking acquired by Mediaocean; Safeguard received $44.8M cash proceeds and recorded $32.3M gain.","Net income of $18.3M ($0.88 per diluted share) vs net loss of $4.3M ($0.21 per share) in Q3 2020.","Cash, cash equivalents and restricted cash totaled $64.2M; carrying value of ownership interests $36.3M at Sept 30, 2021.","General and administrative expenses fell to $1.6M from $2.3M; corporate expenses down 32% to $0.9M."],"consensus_eps_estimate":null,"consensus_eps_actual":1.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8194266.769230769,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":435996,"accession_number":"0001104659-21-112229","cik":86115,"company_name":"SAFEGUARD SCIENTIFICS INC","ticker":"SFES","form_type":"8-K","filed_at":"2021-09-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Safeguard completes Flashtalking sale for $44.8M; launches $35M Dutch auction tender at $7.90-$9.00/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Completed sale of Flashtalking interest for ~$44.8M cash; up to $0.8M additional from escrow over 24 months.","Modified Dutch auction to purchase up to $35M of common stock at $7.90-$9.00/share; expires Oct 1, 2021.","Offer price range above prior day's close of $7.88; management cites commitment to returning value.","CEO Eric Salzman: 'committed to returning value to shareholders when liquidity exceeds needs.'","Board authorizes tender but makes no recommendation; shareholders urged to read offer documents."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":8194266.769230769,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":435995,"accession_number":"0001437749-21-019883","cik":86115,"company_name":"SAFEGUARD SCIENTIFICS INC","ticker":"SFES","form_type":"8-K","filed_at":"2021-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Safeguard Scientifics Q2 2021 earnings call transcript filed; no financial figures in provided excerpt","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Transcript of August 12, 2021 earnings call furnished as Exhibit 99.1; only introductory remarks provided.","CEO Eric Salzman and CFO Mark Herndon participated in the call per operator introduction.","Specific Q2 2021 financial results (revenue, EPS, segment data) not available in the exhibited transcript portion.","Full press release with financial results was filed separately on August 12, 2021, as referenced in Item 2.02."],"consensus_eps_estimate":null,"consensus_eps_actual":0.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":8194266.769230769,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":435994,"accession_number":"0001437749-21-019698","cik":86115,"company_name":"SAFEGUARD SCIENTIFICS INC","ticker":"SFES","form_type":"8-K","filed_at":"2021-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Safeguard Scientifics Q2 net loss narrows to $0.3M; expects $43M from Flashtalking sale","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $0.3M ($0.02 per share) vs loss of $9.9M ($0.48) in Q2 2020; improvement driven by $9.2M in gains.","Receives $3.4M cash from Velano Vascular sale, recording a $1.8M gain; no new deployments in Q2.","Bright Health IPO converted preferred equity to 1,322,484 shares valued at $22.7M (June 30); value fell to ~$11M by Aug 10.","Flashtalking signs definitive agreement to be acquired by Mediaocean; Safeguard expects ~$43M cash in Q3 2021.","Carrying value of ownership interests $60.1M (cost $173.5M); recorded $2.5M impairment on other interests."],"consensus_eps_estimate":null,"consensus_eps_actual":0.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8194266.769230769,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":435993,"accession_number":"0001437749-21-016816","cik":86115,"company_name":"SAFEGUARD SCIENTIFICS INC","ticker":"SFES","form_type":"8-K","filed_at":"2021-07-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Safeguard Scientifics announces Flashtalking acquisition by Mediaocean; expects $43M cash","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Flashtalking, a Safeguard portfolio company, signed definitive agreement to be acquired by Mediaocean.","Safeguard expects approximately $43 million in cash proceeds upon closing.","Transaction expected to close in Q3 2021.","Combined entity will integrate Flashtalking's ad serving and identity management with Mediaocean's omnichannel platform."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":8194266.769230769,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}